{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:01:32Z","timestamp":1794862892289,"version":"4.9.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009543","name":"Pontificia Universidad Javeriana","doi-asserted-by":"publisher","award":["Doctoral scholarship"],"award-info":[{"award-number":["Doctoral scholarship"]}],"id":[{"id":"10.13039\/501100009543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009543","name":"Pontificia Universidad Javeriana","doi-asserted-by":"publisher","award":["ID 20289"],"award-info":[{"award-number":["ID 20289"]}],"id":[{"id":"10.13039\/501100009543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n, Colombia","award":["Contract 120380763212, ID 8352"],"award-info":[{"award-number":["Contract 120380763212, ID 8352"]}]},{"name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n, Colombia","award":["Contract 120380763212, ID 8352"],"award-info":[{"award-number":["Contract 120380763212, ID 8352"]}]},{"name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n, Colombia","award":["Contract 120380763212, ID 8352"],"award-info":[{"award-number":["Contract 120380763212, ID 8352"]}]},{"name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n, Colombia","award":["Contract 120380763212, ID 8352"],"award-info":[{"award-number":["Contract 120380763212, ID 8352"]}]},{"name":"Institute for the Study of Inborn Errors of Metabolism","award":["Activity 120289301011ZZ"],"award-info":[{"award-number":["Activity 120289301011ZZ"]}]},{"name":"Institute for the Study of Inborn Errors of Metabolism","award":["Activity 120289301011ZZ"],"award-info":[{"award-number":["Activity 120289301011ZZ"]}]},{"DOI":"10.13039\/100013927","name":"National MPS Society","doi-asserted-by":"publisher","award":["ID 9509"],"award-info":[{"award-number":["ID 9509"]}],"id":[{"id":"10.13039\/100013927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mucopolysaccharidosis IV A (MPS IVA) is a lysosomal disorder caused by mutations in the <jats:italic>GALNS<\/jats:italic> gene. Consequently, the glycosaminoglycans (GAGs) keratan sulfate and chondroitin 6-sulfate accumulate in the lysosomal lumen. Although enzyme replacement therapy has shown essential advantages for the patients, several challenges remain to overcome, such as the limited impact on the bone lesion and recovery of oxidative profile. Recently, we validated a CRISPR\/nCas9-based gene therapy with promising results in an in vitro MPS IVA model. In this study, we have expanded the use of this CRISPR\/nCas9 system to several MPS IVA fibroblasts carrying different <jats:italic>GALNS<\/jats:italic> mutations. Considering the latent need to develop more safety vectors for gene therapy, we co-delivered the CRISPR\/nCas9 system with a novel non-viral vector based on magnetoliposomes (MLPs). We found that the CRISPR\/nCas9 treatment led to an increase in enzyme activity between 5 and 88% of wild-type levels, as well as a reduction in GAGs accumulation, lysosomal mass, and mitochondrial-dependent oxidative stress, in a mutation-dependent manner. Noteworthy, MLPs allowed to obtain similar results to those observed with the conventional transfection agent lipofectamine. Overall, these results confirmed the potential of CRISPR\/nCas9 as a genome editing tool for treating MPS IVA. We also demonstrated the potential use of MLPs as a novel delivery system for CRISPR\/nCas9-based therapies.<\/jats:p>","DOI":"10.1038\/s41598-022-19407-x","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T12:04:32Z","timestamp":1662206672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Delivery and assessment of a CRISPR\/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-1986","authenticated-orcid":false,"given":"Andr\u00e9s Felipe","family":"Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-3909","authenticated-orcid":false,"given":"Javier","family":"Cifuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7196-7997","authenticated-orcid":false,"given":"Carlos Emilio","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-4706","authenticated-orcid":false,"given":"Diego","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2053-1303","authenticated-orcid":false,"given":"Valentina","family":"Quezada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3459-3225","authenticated-orcid":false,"given":"Sa\u00fal Camilo","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-7546","authenticated-orcid":false,"given":"Juan C.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7251-5298","authenticated-orcid":false,"given":"Luis H.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-6435","authenticated-orcid":false,"given":"Angela Johana","family":"Espejo-Mojica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-1173","authenticated-orcid":false,"given":"Carlos Javier","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"19407_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041517","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto, K. et al. Mucopolysaccharidosis IVA: Diagnosis, treatment, and management. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21041517 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"19407_CR2","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/humu.24270","volume":"42","author":"A Zanetti","year":"2021","unstructured":"Zanetti, A. et al. Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants. Hum. Mutat. 42, 1384\u20131398. https:\/\/doi.org\/10.1002\/humu.24270 (2021).","journal-title":"Hum. Mutat."},{"key":"19407_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymgmr.2017.04.005","volume":"11","author":"B Donida","year":"2017","unstructured":"Donida, B. et al. Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels. Mol. Genet. Metab. Rep. 11, 46\u201353. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.04.005 (2017).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"19407_CR4","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.bbadis.2015.02.004","volume":"1012\u20131019","author":"B Donida","year":"1852","unstructured":"Donida, B. et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim. Biophys. Acta 1012\u20131019, 2015. https:\/\/doi.org\/10.1016\/j.bbadis.2015.02.004 (1852).","journal-title":"Biochim. Biophys. Acta"},{"key":"19407_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100455","volume":"19","author":"H Fujitsuka","year":"2019","unstructured":"Fujitsuka, H. et al. Biomarkers in patients with mucopolysaccharidosis type II and IV. Mol. Genet. Metab. Rep. 19, 100455. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100455 (2019).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"19407_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010226","author":"VJ \u00c1lvarez","year":"2020","unstructured":"\u00c1lvarez, V. J. et al. Characterization of new proteomic biomarker candidates in mucopolysaccharidosis type IVA. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22010226 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"19407_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184610","author":"JV \u00c1lvarez","year":"2019","unstructured":"\u00c1lvarez, J. V. et al. Proteomic analysis in Morquio A cells treated with immobilized enzymatic replacement therapy on nanostructured lipid systems. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20184610 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"19407_CR8","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1038\/s41467-021-25697-y","volume":"12","author":"J Bertolin","year":"2021","unstructured":"Bertolin, J. et al. Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy. Nat. Commun. 12, 5343. https:\/\/doi.org\/10.1038\/s41467-021-25697-y (2021).","journal-title":"Nat. Commun."},{"key":"19407_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020273","author":"B \u00c7elik","year":"2021","unstructured":"\u00c7elik, B., Tomatsu, S. C., Tomatsu, S. & Khan, S. A. Epidemiology of mucopolysaccharidoses update. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics11020273 (2021).","journal-title":"Diagnostics (Basel)."},{"key":"19407_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.7705\/biomedica.v32i4.574","volume":"32","author":"AM G\u00f3mez","year":"2012","unstructured":"G\u00f3mez, A. M., Garc\u00eda-Robles, R. & Su\u00e1rez-Obando, F. Estimation of the mucopolysaccharidoses frequencies and cluster analysis in the Colombian Provinces of Cundinamarca and Boyac\u00e1. Biom\u00e9dica. 32, 602\u2013609 (2012).","journal-title":"Biom\u00e9dica"},{"key":"19407_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00344-3","author":"AF Leal","year":"2022","unstructured":"Leal, A. F. & Almeciga-Diaz, C. J. Efficient CRISPR\/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-022-00344-3 (2022).","journal-title":"Gene Ther."},{"key":"19407_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.omtm.2020.05.015","volume":"18","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto, K. et al. Liver-targeted AAV8 gene therapy ameliorates skeletal and cardiovascular pathology in a mucopolysaccharidosis IVA murine model. Mol. Ther. Methods Clin. Dev. 18, 50\u201361. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.015 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"19407_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41390-018-0095-8","volume":"84","author":"CJ Alm\u00e9ciga-D\u00edaz","year":"2018","unstructured":"Alm\u00e9ciga-D\u00edaz, C. J., Monta\u00f1o, A. M., Barrera, L. A. & Tomatsu, S. Tailoring the AAV2 capsid vector for bone-targeting. Pediatr. Res. 84, 545\u2013551. https:\/\/doi.org\/10.1038\/s41390-018-0095-8 (2018).","journal-title":"Pediatr. Res."},{"key":"19407_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target Ther. 6, 53. https:\/\/doi.org\/10.1038\/s41392-021-00487-6 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"19407_CR15","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.drudis.2021.03.021","volume":"26","author":"NA Alhakamy","year":"2021","unstructured":"Alhakamy, N. A., Curiel, D. T. & Berkland, C. J. The era of gene therapy: From preclinical development to clinical application. Drug Discov. Today 26, 1602\u20131619. https:\/\/doi.org\/10.1016\/j.drudis.2021.03.021 (2021).","journal-title":"Drug Discov. Today"},{"key":"19407_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01935-6","author":"AF Leal","year":"2020","unstructured":"Leal, A. F. et al. Lysosomal storage diseases: Current therapies and future alternatives. J. Mol. Med. (Berl). https:\/\/doi.org\/10.1007\/s00109-020-01935-6 (2020).","journal-title":"J. Mol. Med. (Berl)."},{"key":"19407_CR17","doi-asserted-by":"publisher","first-page":"24356","DOI":"10.1038\/srep24356","volume":"6","author":"TW Chiang","year":"2016","unstructured":"Chiang, T. W., le Sage, C., Larrieu, D., Demir, M. & Jackson, S. P. CRISPR-Cas 9(D10A) nickase-based genotypic and phenotypic screening to enhance genome editing. Sci. Rep. 6, 24356. https:\/\/doi.org\/10.1038\/srep24356 (2016).","journal-title":"Sci. Rep."},{"key":"19407_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158287","author":"SM Caruso","year":"2022","unstructured":"Caruso, S. M., Quinn, P. M., da Costa, B. L. & Tsang, S. H. CRISPR\/Cas therapeutic strategies for autosomal dominant disorders. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI158287 (2022).","journal-title":"J. Clin. Invest."},{"key":"19407_CR19","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1038\/s41467-020-17148-x","volume":"11","author":"SG Scharenberg","year":"2020","unstructured":"Scharenberg, S. G. et al. Engineering monocyte\/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing. Nat. Commun. 11, 3327. https:\/\/doi.org\/10.1038\/s41467-020-17148-x (2020).","journal-title":"Nat. Commun."},{"key":"19407_CR20","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1038\/s41467-019-11962-8","volume":"10","author":"N Gomez-Ospina","year":"2019","unstructured":"Gomez-Ospina, N. et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nat. Commun. 10, 4045. https:\/\/doi.org\/10.1038\/s41467-019-11962-8 (2019).","journal-title":"Nat. Commun."},{"key":"19407_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41434-019-0113-4","volume":"27","author":"RS Schuh","year":"2020","unstructured":"Schuh, R. S. et al. Neonatal nonviral gene editing with the CRISPR\/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice. Gene Ther. 27, 74\u201384. https:\/\/doi.org\/10.1038\/s41434-019-0113-4 (2020).","journal-title":"Gene Ther."},{"key":"19407_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gene.2018.08.004","volume":"678","author":"TG de Carvalho","year":"2018","unstructured":"de Carvalho, T. G. et al. CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts. Gene 678, 33\u201337. https:\/\/doi.org\/10.1016\/j.gene.2018.08.004 (2018).","journal-title":"Gene"},{"key":"19407_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11095-018-2503-5","volume":"35","author":"RS Schuh","year":"2018","unstructured":"Schuh, R. S. et al. Nasal administration of cationic nanoemulsions as nucleic acids delivery systems aiming at mucopolysaccharidosis type I gene therapy. Pharm. Res. 35, 221. https:\/\/doi.org\/10.1007\/s11095-018-2503-5 (2018).","journal-title":"Pharm. Res."},{"key":"19407_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejpb.2017.10.017","volume":"122","author":"RS Schuh","year":"2018","unstructured":"Schuh, R. S. et al. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR\/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers. Eur. J. Pharm. Biopharm. 122, 158\u2013166. https:\/\/doi.org\/10.1016\/j.ejpb.2017.10.017 (2018).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"19407_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","volume":"288","author":"RS Schuh","year":"2018","unstructured":"Schuh, R. S. et al. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR\/Cas9 system. J. Controlled Release 288, 23\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.031 (2018).","journal-title":"J. Controlled Release"},{"key":"19407_CR26","doi-asserted-by":"crossref","unstructured":"Leal, A. F., Espejo-Mojica, A. J. & Alm\u00e9ciga-D\u00edaz, C. J. Vol. 135 (Molecular enetics and etabolism, 2022).","DOI":"10.1016\/j.ymgme.2021.11.183"},{"key":"19407_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-019-0120-5","author":"L Ou","year":"2020","unstructured":"Ou, L. et al. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-019-0120-5 (2020).","journal-title":"Gene Ther."},{"key":"19407_CR28","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","volume":"12","author":"A Khan","year":"2021","unstructured":"Khan, A. et al. Lentivirus-mediated gene therapy for Fabry disease. Nat. Commun. 12, 1178. https:\/\/doi.org\/10.1038\/s41467-021-21371-5 (2021).","journal-title":"Nat. Commun."},{"key":"19407_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41434-019-0086-3","volume":"27","author":"CJ Alm\u00e9ciga-Diaz","year":"2020","unstructured":"Alm\u00e9ciga-Diaz, C. J. & Barrera, L. A. Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia. Gene Ther. 27, 104\u2013107. https:\/\/doi.org\/10.1038\/s41434-019-0086-3 (2020).","journal-title":"Gene Ther."},{"key":"19407_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215491","author":"S Patil","year":"2019","unstructured":"Patil, S. et al. The development of functional non-viral vectors for gene delivery. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20215491 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"19407_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060561","author":"CM Ram\u00edrez-Acosta","year":"2020","unstructured":"Ram\u00edrez-Acosta, C. M. et al. PH-responsive, cell-penetrating, core\/shell magnetite\/silver nanoparticles for the delivery of plasmids: Preparation, characterization, and preliminary. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics12060561 (2020).","journal-title":"Pharmaceutics."},{"key":"19407_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/nano10091857","author":"CM Ram\u00edrez-Acosta","year":"2020","unstructured":"Ram\u00edrez-Acosta, C. M., Cifuentes, J., Cruz, J. C. & Reyes, L. H. Patchy core\/shell, magnetite\/silver nanoparticles via green and facile synthesis: Routes to assure biocompatibility. Nanomaterials (Basel). https:\/\/doi.org\/10.3390\/nano10091857 (2020).","journal-title":"Nanomaterials (Basel)."},{"key":"19407_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020315","author":"CE Torres","year":"2022","unstructured":"Torres, C. E. et al. Microfluidic synthesis and purification of magnetoliposomes for potential applications in the gastrointestinal delivery of difficult-to-transport drugs. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14020315 (2022).","journal-title":"Pharmaceutics."},{"key":"19407_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12033-018-0145-9","volume":"61","author":"M Hryhorowicz","year":"2019","unstructured":"Hryhorowicz, M. et al. Improved delivery of CRISPR\/Cas9 system using magnetic nanoparticles into porcine fibroblast. Mol. Biotechnol. 61, 173\u2013180. https:\/\/doi.org\/10.1007\/s12033-018-0145-9 (2019).","journal-title":"Mol. Biotechnol."},{"key":"19407_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145527","volume":"780","author":"MA Puentes-Tellez","year":"2021","unstructured":"Puentes-Tellez, M. A. et al. Evaluation of HIV-1 derived lentiviral vectors as transductors of Mucopolysaccharidosis type IV a fibroblasts. Gene 780, 145527. https:\/\/doi.org\/10.1016\/j.gene.2021.145527 (2021).","journal-title":"Gene"},{"key":"19407_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ymgme.2015.08.001","volume":"117","author":"DA Salazar","year":"2016","unstructured":"Salazar, D. A. et al. Systems biology study of mucopolysaccharidosis using a human metabolic reconstruction network. Mol. Genet. Metab. 117, 129\u2013139. https:\/\/doi.org\/10.1016\/j.ymgme.2015.08.001 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"19407_CR37","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1093\/hmg\/ddg366","volume":"12","author":"S Tomatsu","year":"2003","unstructured":"Tomatsu, S. et al. Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns\u2212\/\u2212) produced by targeted disruption of the gene defective in Morquio A disease. Hum. Mol. Genet. 12, 3349\u20133358. https:\/\/doi.org\/10.1093\/hmg\/ddg366 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"19407_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020420","author":"MU Kuk","year":"2021","unstructured":"Kuk, M. U. et al. Potential treatment of lysosomal storage disease through modulation of the mitochondrial-lysosomal axis. Cells https:\/\/doi.org\/10.3390\/cells10020420 (2021).","journal-title":"Cells"},{"key":"19407_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang, F. & Doudna, J. A. CRISPR-Cas9 structures and mechanisms. Annu. Rev. Biophys. 46, 505\u2013529. https:\/\/doi.org\/10.1146\/annurev-biophys-062215-010822 (2017).","journal-title":"Annu. Rev. Biophys."},{"key":"19407_CR40","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/17425247.2021.1915983","volume":"18","author":"SRS Veloso","year":"2021","unstructured":"Veloso, S. R. S., Andrade, R. G. D. & Castanheira, E. M. S. Magnetoliposomes: Recent advances in the field of controlled drug delivery. Expert Opin. Drug Deliv. 18, 1323\u20131334. https:\/\/doi.org\/10.1080\/17425247.2021.1915983 (2021).","journal-title":"Expert Opin. Drug Deliv."},{"key":"19407_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2021.06.016","volume":"336","author":"B Halamoda-Kenzaoui","year":"2021","unstructured":"Halamoda-Kenzaoui, B. et al. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation. J. Control Release 336, 192\u2013206. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.016 (2021).","journal-title":"J. Control Release"},{"key":"19407_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10246","author":"AC Anselmo","year":"2021","unstructured":"Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic: An update post COVID-19 vaccines. Bioeng. Transl. Med. https:\/\/doi.org\/10.1002\/btm2.10246 (2021).","journal-title":"Bioeng. Transl. Med."},{"key":"19407_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12951-020-0580-1","volume":"18","author":"SM Dadfar","year":"2020","unstructured":"Dadfar, S. M. et al. Size-isolation of superparamagnetic iron oxide nanoparticles improves MRI, MPI and hyperthermia performance. J. Nanobiotechnol. 18, 22. https:\/\/doi.org\/10.1186\/s12951-020-0580-1 (2020).","journal-title":"J. Nanobiotechnol."},{"key":"19407_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s13197-021-05184-4","author":"A Kumari","year":"2021","unstructured":"Kumari, A. & Chauhan, A. K. Iron nanoparticles as a promising compound for food fortification in iron deficiency anemia: A review. J. Food Sci. Technol. https:\/\/doi.org\/10.1007\/s13197-021-05184-4 (2021).","journal-title":"J. Food Sci. Technol."},{"key":"19407_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101\u2013124. https:\/\/doi.org\/10.1038\/s41573-020-0090-8 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"19407_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1109\/LMAG.2016.2629458","volume":"8","author":"JS Matahum","year":"2017","unstructured":"Matahum, J. S., Su, C. M., Wang, W. J., Lou, S. L. & Ger, T. R. Effect of surface charge on the uptake of magnetic nanoparticles in mouse fibroblast cells. IEEE Magnet. Lett. 8, 1\u20135. https:\/\/doi.org\/10.1109\/LMAG.2016.2629458 (2017).","journal-title":"IEEE Magnet. Lett."},{"key":"19407_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.761045","volume":"11","author":"S Kraus","year":"2021","unstructured":"Kraus, S. et al. Novel nanoparticle-based cancer treatment, effectively inhibits lung metastases and improves survival in a murine breast cancer model. Front. Oncol. 11, 761045. https:\/\/doi.org\/10.3389\/fonc.2021.761045 (2021).","journal-title":"Front. Oncol."},{"key":"19407_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.12.002","volume":"342","author":"GD Keeler","year":"2019","unstructured":"Keeler, G. D., Markusic, D. M. & Hoffman, B. E. Liver induced transgene tolerance with AAV vectors. Cell Immunol. 342, 103728. https:\/\/doi.org\/10.1016\/j.cellimm.2017.12.002 (2019).","journal-title":"Cell Immunol."},{"key":"19407_CR49","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1039\/d0cs01127d","volume":"50","author":"M Sousa de Almeida","year":"2021","unstructured":"Sousa de Almeida, M. et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem. Soc. Rev. 50, 5397\u20135434. https:\/\/doi.org\/10.1039\/d0cs01127d (2021).","journal-title":"Chem. Soc. Rev."},{"key":"19407_CR50","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10948-021-05932-9","volume":"34","author":"E Kianfar","year":"2021","unstructured":"Kianfar, E. Magnetic nanoparticles in targeted drug delivery: A review. J. Supercond. Nov. Magn. 34, 1709\u20131735. https:\/\/doi.org\/10.1007\/s10948-021-05932-9 (2021).","journal-title":"J. Supercond. Nov. Magn."},{"key":"19407_CR51","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jconrel.2020.07.032","volume":"326","author":"SH Lee","year":"2020","unstructured":"Lee, S. H. et al. Endocytic trafficking of polymeric clustered superparamagnetic iron oxide nanoparticles in mesenchymal stem cells. J. Control Release 326, 408\u2013418. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.032 (2020).","journal-title":"J. Control Release"},{"key":"19407_CR52","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.1021\/acsami.0c20066","volume":"13","author":"Y Portilla","year":"2021","unstructured":"Portilla, Y. et al. Iron oxide nanoparticle coatings dictate cell outcomes despite the influence of protein coronas. ACS Appl. Mater. Interfaces 13, 7924\u20137944. https:\/\/doi.org\/10.1021\/acsami.0c20066 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"19407_CR53","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3762\/bjnano.12.22","volume":"12","author":"B Svitkova","year":"2021","unstructured":"Svitkova, B. et al. Differences in surface chemistry of iron oxide nanoparticles result in different routes of internalization. Beilstein J. Nanotechnol. 12, 270\u2013281. https:\/\/doi.org\/10.3762\/bjnano.12.22 (2021).","journal-title":"Beilstein J. Nanotechnol."},{"key":"19407_CR54","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.2147\/IJN.S321984","volume":"16","author":"H Wei","year":"2021","unstructured":"Wei, H. et al. Superparamagnetic iron oxide nanoparticles: Cytotoxicity, metabolism, and cellular behavior in biomedicine applications. Int. J. Nanomed. 16, 6097\u20136113. https:\/\/doi.org\/10.2147\/IJN.S321984 (2021).","journal-title":"Int. J. Nanomed."},{"key":"19407_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/cbin.11332","volume":"45","author":"J Brokowska","year":"2021","unstructured":"Brokowska, J., Pierzynowska, K., Gaffke, L., Rintz, E. & W\u0119grzyn, G. Expression of genes involved in apoptosis is dysregulated in mucopolysaccharidoses as revealed by pilot transcriptomic analyses. Cell Biol. Int. 45, 549\u2013557. https:\/\/doi.org\/10.1002\/cbin.11332 (2021).","journal-title":"Cell Biol. Int."},{"key":"19407_CR56","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1080\/10717544.2020.1775724","volume":"27","author":"N Lopez-Barbosa","year":"2020","unstructured":"Lopez-Barbosa, N. et al. Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer\u2019s. Drug Deliv. 27, 864\u2013875. https:\/\/doi.org\/10.1080\/10717544.2020.1775724 (2020).","journal-title":"Drug Deliv."},{"key":"19407_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s11051-020-04833-7","author":"RFL Ribeiro","year":"2020","unstructured":"Ribeiro, R. F. L. et al. Cytotoxic effect of thermosensitive magnetoliposomes loaded with gemcitabine and paclitaxel on human primary breast cancer cells (MGSO-3 line). J. Nanopart. Res. https:\/\/doi.org\/10.1007\/s11051-020-04833-7 (2020).","journal-title":"J. Nanopart. Res."},{"key":"19407_CR58","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jmb.2012.08.020","volume":"423","author":"Y Rivera-Col\u00f3n","year":"2012","unstructured":"Rivera-Col\u00f3n, Y., Schutsky, E. K., Kita, A. Z. & Garman, S. C. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. J. Mol. Biol. 423, 736\u2013751. https:\/\/doi.org\/10.1016\/j.jmb.2012.08.020 (2012).","journal-title":"J. Mol. Biol."},{"key":"19407_CR59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jnc.14564","volume":"148","author":"L Bajaj","year":"2019","unstructured":"Bajaj, L. et al. Lysosome biogenesis in health and disease. J. Neurochem. 148, 573\u2013589. https:\/\/doi.org\/10.1111\/jnc.14564 (2019).","journal-title":"J. Neurochem."},{"key":"19407_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1074\/mcp.RA118.000967","volume":"18","author":"T \u010caval","year":"2019","unstructured":"\u010caval, T. et al. Targeted analysis of lysosomal directed proteins and their sites of mannose-6-phosphate modification. Mol. Cell Proteom. 18, 16\u201327. https:\/\/doi.org\/10.1074\/mcp.RA118.000967 (2019).","journal-title":"Mol. Cell Proteom."},{"key":"19407_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052766","author":"L Gaffke","year":"2021","unstructured":"Gaffke, L. et al. Gene expression-related changes in morphologies of organelles and cellular component organization in mucopolysaccharidoses. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22052766 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"19407_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cellsig.2015.10.013","volume":"28","author":"E Borkham-Kamphorst","year":"2016","unstructured":"Borkham-Kamphorst, E. et al. CCN1\/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. Cell Signal 28, 34\u201342. https:\/\/doi.org\/10.1016\/j.cellsig.2015.10.013 (2016).","journal-title":"Cell Signal"},{"key":"19407_CR63","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/bit.20566","volume":"91","author":"J Jones","year":"2005","unstructured":"Jones, J. et al. Optimization of tetracycline-responsive recombinant protein production and effect on cell growth and ER stress in mammalian cells. Biotechnol. Bioeng. 91, 722\u2013732. https:\/\/doi.org\/10.1002\/bit.20566 (2005).","journal-title":"Biotechnol. Bioeng."},{"key":"19407_CR64","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1021\/acsmedchemlett.0c00042","volume":"11","author":"S Olarte-Avellaneda","year":"2020","unstructured":"Olarte-Avellaneda, S. et al. Bromocriptine as a novel pharmacological chaperone for mucopolysaccharidosis IV A. ACS Med. Chem. Lett. 11, 1377\u20131385. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00042 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"19407_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082596","author":"KM Stepien","year":"2020","unstructured":"Stepien, K. M. et al. Mechanisms of mitochondrial dysfunction in lysosomal storage disorders: A review. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm9082596 (2020).","journal-title":"J. Clin. Med."},{"key":"19407_CR66","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1007\/s11033-008-9392-3","volume":"36","author":"CJ Alm\u00e9ciga-D\u00edaz","year":"2009","unstructured":"Alm\u00e9ciga-D\u00edaz, C. J. et al. Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase. Mol. Biol. Rep. 36, 1863\u20131870. https:\/\/doi.org\/10.1007\/s11033-008-9392-3 (2009).","journal-title":"Mol. Biol. Rep."},{"key":"19407_CR67","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1021\/acs.jmedchem.9b00428","volume":"62","author":"CJ Almeciga-Diaz","year":"2019","unstructured":"Almeciga-Diaz, C. J. et al. Identification of ezetimibe and pranlukast as pharmacological chaperones for the treatment of the rare disease mucopolysaccharidosis type IVA. J. Med. Chem. 62, 6175\u20136189. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00428 (2019).","journal-title":"J. Med. Chem."},{"key":"19407_CR68","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ymgme.2014.03.004","volume":"112","author":"A Morrone","year":"2014","unstructured":"Morrone, A. et al. Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol. Genet. Metab. 112, 160\u2013170. https:\/\/doi.org\/10.1016\/j.ymgme.2014.03.004 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"19407_CR69","doi-asserted-by":"crossref","unstructured":"Hassan, S., Sidransky, E. & Tayebi, N. The role of epigenetics in lysosomal storage disorders: Uncharted territory. 10\u201318 (2017).","DOI":"10.1016\/j.ymgme.2017.07.012"},{"key":"19407_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2003.018010","volume":"41","author":"S Tomatsu","year":"2004","unstructured":"Tomatsu, S. et al. Mucopolysaccharidosis IVA: Identification of mutations and methylation study in GALNS gene. J. Med. Genet. 41, e98 (2004).","journal-title":"J. Med. Genet."},{"key":"19407_CR71","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.ymgme.2021.11.329","volume":"135","author":"V Vargas-L\u00f3pez","year":"2022","unstructured":"Vargas-L\u00f3pez, V. & Alm\u00e9ciga-D\u00edaz, C. J. Epigenetic changes in fibroblast from patients with mucopolysaccharidoses. Mol. Genet. Metab. 135, S123\u2013S124 (2022).","journal-title":"Mol. Genet. Metab."},{"key":"19407_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.chemphyslip.2013.10.011","volume":"177","author":"YP Patil","year":"2014","unstructured":"Patil, Y. P. & Jadhav, S. Novel methods for liposome preparation. Chem. Phys. Lipids 177, 8\u201318. https:\/\/doi.org\/10.1016\/j.chemphyslip.2013.10.011 (2014).","journal-title":"Chem. Phys. Lipids"},{"key":"19407_CR73","doi-asserted-by":"publisher","first-page":"15120","DOI":"10.1038\/s41598-019-51065-4","volume":"9","author":"H Elsana","year":"2019","unstructured":"Elsana, H. et al. Evaluation of novel cationic gene based liposomes with cyclodextrin prepared by thin film hydration and microfluidic systems. Sci. Rep. 9, 15120. https:\/\/doi.org\/10.1038\/s41598-019-51065-4 (2019).","journal-title":"Sci. Rep."},{"key":"19407_CR74","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.7150\/thno.4240","volume":"2","author":"CM Panje","year":"2012","unstructured":"Panje, C. M. et al. Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: Effect of DNA and microbubble dose on in vivo transfection efficiency. Theranostics 2, 1078\u20131091. https:\/\/doi.org\/10.7150\/thno.4240 (2012).","journal-title":"Theranostics"},{"key":"19407_CR75","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089 (2012).","journal-title":"Nat. Methods"},{"key":"19407_CR76","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.mrfmmm.2006.06.001","volume":"601","author":"C Fimognari","year":"2006","unstructured":"Fimognari, C. et al. Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. Mutat. Res. 601, 92\u2013101. https:\/\/doi.org\/10.1016\/j.mrfmmm.2006.06.001 (2006).","journal-title":"Mutat. Res."},{"key":"19407_CR77","doi-asserted-by":"publisher","first-page":"13478","DOI":"10.1074\/jbc.M308523200","volume":"279","author":"MB Tropak","year":"2004","unstructured":"Tropak, M. B., Reid, S. P., Guiral, M., Withers, S. G. & Mahuran, D. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J. Biol. Chem. 279, 13478\u201313487. https:\/\/doi.org\/10.1074\/jbc.M308523200 (2004).","journal-title":"J. Biol. Chem."},{"key":"19407_CR78","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajmg.c.31849","volume":"184","author":"AJ Espejo-Mojica","year":"2020","unstructured":"Espejo-Mojica, A. J. et al. Human recombinant lysosomal \u03b2-Hexosaminidases produced in Pichia pastoris efficiently reduced lipid accumulation in Tay-Sachs fibroblasts. Am. J. Med. Genet. C Semin. Med. Genet. 184, 885\u2013895. https:\/\/doi.org\/10.1002\/ajmg.c.31849 (2020).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"19407_CR79","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajmg.c.31849","volume":"21","author":"AJ Espejo-Mojica","year":"2016","unstructured":"Espejo-Mojica, A. J. et al. Characterization of recombinant human lysosomal beta-hexosaminidases produced in the methylotrophic yeast Pichia pastoris. Univ. Sci. 21, 195\u2013217 (2016).","journal-title":"Univ. Sci"},{"key":"19407_CR80","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.freeradbiomed.2007.04.026","volume":"43","author":"NS Bryan","year":"2007","unstructured":"Bryan, N. S. & Grisham, M. B. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic. Biol. Med. 43, 645\u2013657. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2007.04.026 (2007).","journal-title":"Free Radic. Biol. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19407-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19407-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19407-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:02:33Z","timestamp":1662249753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19407-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19407"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19407-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15045"}}